Skip to main content

Advertisement

SpringerLink
Log in

Proton pump inhibitors: use, misuse and concerns about long-term therapy

  • Clinical Review
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Proton pump inhibitors (PPIs) are widely used in acid-related disorders of the stomach and oesophagus. Treatment with PPIs is usually extended indefinitely for maintaining symptom control, putting the patient at risk of adverse effects. On the other hand, there is also a tendency for physicians to prescribe these drugs unnecessarily for minor dyspepsia. The use of these best-selling drugs is expected to increase further as they are now available over-the-counter in many countries . Several newer PPIs are now available on the market with claims of superior therapeutic efficacy which are also excessively prescribed without considering their cost-effectiveness. This article examines why PPIs are now the leading antisecretory drugs, clinical aspects to be considered when prescribing newer PPIs, indications and recommended duration of treatment in each situation, over-prescription of PPIs, and adverse reactions that can emerge with long-term use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. IMS Health Midas, December 2009.

  2. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83:66–8.

    Article  PubMed  Google Scholar 

  3. Pillans PI, Kubler PA, Radford JM, Overland V, et al. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust. 2000;172:16–8.

    PubMed  CAS  Google Scholar 

  4. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S, et al. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277–305.

    Article  PubMed  CAS  Google Scholar 

  5. Brunton LL, Goodman LS, Blumenthal D, et al. Goodman and Gilman’s manual of pharmacology and therapeutics. McGraw-Hill Professional; 2007. 624p.

  6. Sachs G. Therapeutic control of acid secretion: pharmacology of the parietal cell. Curr Opin Gastroenterol. 1990;6:859–66.

    Article  Google Scholar 

  7. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology. 1994;106:60–4.

    PubMed  CAS  Google Scholar 

  8. Khoshbaten M, Fattahi E, Naderi N, Khaleghian F, Rezailashkajani M, et al. A comparison of oral omeprazole and intravenous cimetidine in reducing complications of duodenal peptic ulcer. BMC Gastroenterol. 2006;6:2.

    Article  PubMed  Google Scholar 

  9. Lanas A, Artal A, Blás JM, Arroyo MT, Lopez-Zaborras J, Sáinz R. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol. 1995;21:103–6.

    Article  PubMed  CAS  Google Scholar 

  10. Sung JJ, Chan FK, Lau JY, Yung MY, Leung WK, Wu JC, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison. Ann Intern Med. 2003;139:237–43.

    PubMed  CAS  Google Scholar 

  11. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:1–164.

    Google Scholar 

  12. Salas M, Ward A, Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol. 2002;2:17.

    Article  PubMed  Google Scholar 

  13. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists—their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:757–66.

    Article  PubMed  CAS  Google Scholar 

  14. Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Robinson M. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol. 1997;92:429–37.

    PubMed  CAS  Google Scholar 

  15. Feldman M, Harford WV, Fisher RS, Sampliner RE, Murray SB, Greski-Rose PA, et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. Am J Gastroenterol. 1993;88:1212–7.

    PubMed  CAS  Google Scholar 

  16. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10:529–39.

    Article  PubMed  CAS  Google Scholar 

  17. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006;44:297–302.

    PubMed  CAS  Google Scholar 

  18. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63:2739–54.

    Article  PubMed  CAS  Google Scholar 

  19. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008;13:532–41.

    Article  PubMed  Google Scholar 

  20. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Pharmacol Ther. 2000;14:963–78.

    CAS  Google Scholar 

  21. Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31–4.

    Article  PubMed  CAS  Google Scholar 

  22. Blume H, Donath F, Warnke A, Schug BS, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769–84.

    Article  PubMed  CAS  Google Scholar 

  23. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol. 1995;7:661–5.

    PubMed  CAS  Google Scholar 

  24. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23:998–1017.

    Article  PubMed  CAS  Google Scholar 

  25. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer—a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1998;12:789–95.

    Article  PubMed  CAS  Google Scholar 

  26. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98:2616–20.

    Article  PubMed  CAS  Google Scholar 

  27. Jones R, Patrikios T. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor. Int J Clin Pract. 2008;62:1844–50.

    Article  PubMed  CAS  Google Scholar 

  28. Thomson AB. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep. 2000;2:482–93.

    Article  PubMed  CAS  Google Scholar 

  29. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther. 2003;17:1237–45.

    Article  PubMed  CAS  Google Scholar 

  30. Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology. 2008;134:1836–41.

    Article  PubMed  Google Scholar 

  31. Javid G, Zargar SA, U-Saif R, Khan BA, Yatoo GN, Shah AH, et al. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. J Gastroenterol Hepatol. 2009;24:1236–43.

    Article  PubMed  CAS  Google Scholar 

  32. Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord. 2005;5:18–30.

    Google Scholar 

  33. Guda NM, Noonan M, Kreiner MJ, Partington S, Vakil N. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol. 2004;99:1233–7.

    Article  PubMed  CAS  Google Scholar 

  34. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther. 2001;15:347–54.

    Article  PubMed  CAS  Google Scholar 

  35. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis— a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907–14.

    Article  PubMed  CAS  Google Scholar 

  36. Malfertheiner P, Megraud F, O’Morain C. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.

    Article  PubMed  CAS  Google Scholar 

  37. Liu CC, Lee CL, Chan CC, Tu TC, Liao CC, Wu CH, et al. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. Arch Intern Med. 2003;163:2020–4.

    Article  PubMed  Google Scholar 

  38. Metz DC, Inadomi JM, Howden CW. On-demand therapy for gastroesophageal reflux disease. J Gastroenterol. 2007;102:642–53.

    Google Scholar 

  39. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;4. Art. no: CD001960.

  40. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383–91.

    Article  PubMed  Google Scholar 

  41. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial. Gut. 2004;53:12–20.

    Article  PubMed  CAS  Google Scholar 

  42. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19:197–208.

    Article  PubMed  CAS  Google Scholar 

  43. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016–21.

    Article  PubMed  CAS  Google Scholar 

  44. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32.

    Article  PubMed  CAS  Google Scholar 

  45. Poynard T. Critical study of gastroduodenal complications of corticotherapy. Rev Prat. 1990;40:553–5.

    Google Scholar 

  46. Kantorova I, Svoboda P, Scheer P, Doubek J, Rehorkova D, Bosakova H, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004;51:757–61.

    PubMed  Google Scholar 

  47. Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am. 2009;38:245–65.

    Article  PubMed  Google Scholar 

  48. Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis. J Med Assoc Thai. 2009;92:632–7.

    PubMed  Google Scholar 

  49. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ. 1998;317:452–6.

    PubMed  CAS  Google Scholar 

  50. Levy-Neumand O, Carniaux F, Bonaz B, Durand A, Roblin X, et al. Proton pump inhibitors in general medicine. Comparison of routine practices with marketing authorization indications. Gastroenterol Clin Biol. 2007;31:78–83.

    Article  PubMed  Google Scholar 

  51. Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24:945–54.

    Article  PubMed  Google Scholar 

  52. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323–30.

    Article  PubMed  CAS  Google Scholar 

  53. Wong H, Yau T, Chan P, Ng IO, Chan G, Hui P, et al. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res. 2010;16:87–91.

    Article  PubMed  Google Scholar 

  54. Corleto VD, Annibale B, Gibril F, Angeletti S, Serrano J, Venzon DJ, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger–Ellison syndrome? Aliment Pharmacol Ther. 2001;15:1555–61.

    Article  PubMed  CAS  Google Scholar 

  55. Genta RM, Schuler CM, Robiou CI, Lash RH. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol. 2009;7:849–54.

    Article  PubMed  Google Scholar 

  56. Kim JS, Chae HS, Kim HK, Cho YS, Park YW, Son HS, et al. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with omeprazole. Korean J Gastroenterol. 2008;51:305–8.

    PubMed  Google Scholar 

  57. el-Zimaity HMT, Frank WJ, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol. 1997;92:1858–60.

    PubMed  CAS  Google Scholar 

  58. Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol. 2001;116:716–20.

    Article  PubMed  CAS  Google Scholar 

  59. Hsu WH, Wu IC, Kuo CH, Su YC, Lu CY, Kuo FC, et al. Influence of proton pump inhibitor use in gastrointestinal polyps. Kaohsiung J Med Sci. 2010;26:76–83.

    Article  PubMed  CAS  Google Scholar 

  60. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001;64:205–13.

    Article  PubMed  CAS  Google Scholar 

  61. Graham DY, Genta RM. Long term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep. 2008;10:543–7.

    Article  PubMed  Google Scholar 

  62. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133:748–54.

    Article  PubMed  CAS  Google Scholar 

  63. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case−control study. Gastroenterology. 2007;133:755–60.

    Article  PubMed  Google Scholar 

  64. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology. 1997;112:707–17.

    Article  PubMed  CAS  Google Scholar 

  65. Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55:2431–40.

    Article  PubMed  CAS  Google Scholar 

  66. Sipponen P, Härkönen M. Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol. 2010;45:133–8.

    Article  PubMed  CAS  Google Scholar 

  67. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.

    Article  PubMed  CAS  Google Scholar 

  68. Johnson DA. Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents. Curr Gastroenterol Rep. 2010;12:167–74.

    Article  PubMed  Google Scholar 

  69. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case−control study. Pharmacoepidemiol Drug Saf. 2010;19:792–802.

    Article  PubMed  CAS  Google Scholar 

  70. Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123:47–53.

    Article  PubMed  CAS  Google Scholar 

  71. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–44.

    Article  PubMed  CAS  Google Scholar 

  72. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713–8.

    Article  PubMed  Google Scholar 

  73. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989–97.

    Article  PubMed  Google Scholar 

  74. Liu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors. Pharmacotherapy. 2010;30:275–89.

    Article  PubMed  Google Scholar 

  75. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714–9.

    PubMed  CAS  Google Scholar 

  76. Norgard NB, Mathews KD, Wall GC. Drug–drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43:1266–74.

    Article  PubMed  CAS  Google Scholar 

  77. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol. 2010;105:34–41.

    Article  PubMed  CAS  Google Scholar 

  78. Chow CK, Moayyedi P, Devereaux PJ. Is it safe to use a proton pump inhibitor with clopidogrel? Pol Arch Med Wewn. 2009;119:564–8.

    PubMed  CAS  Google Scholar 

  79. Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153:378–86.

    PubMed  Google Scholar 

  80. Labenz J, Petersen KU, Rösch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2003;17:1015–9.

    Article  PubMed  CAS  Google Scholar 

  81. Sennaroglu E, Karakan S, Kayatas M, Akdur S, Genc H, Karakan T, et al. Reversible edema in a male patient taking parenteral pantoprazole infusion for pyloric stenosis. Dig Dis Sci. 2006;51:121–2.

    Article  PubMed  Google Scholar 

  82. Brunner G, Athmann C, Boldt JH. Reversible peripheral edema in female patients taking proton pump inhibitors for peptic acid diseases. Dig Dis Sci. 2001;46:993–6.

    Article  PubMed  CAS  Google Scholar 

  83. Grau Amorós J. Erectile dysfunction and proton pump inhibitors. Med Clin (Barc). 2000;114:478.

    Google Scholar 

  84. Bong JL, Lucke TW, Douglas WS. Lichenoid drug eruption with proton pump inhibitors. BMJ. 2000;320:283.

    Article  PubMed  CAS  Google Scholar 

  85. Darabi K. Proton-pump-inhibitor-induced hepatitis. South Med J. 2005;98:844–5.

    Article  PubMed  Google Scholar 

  86. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545–53.

    Article  PubMed  CAS  Google Scholar 

  87. Fallahzadeh MK, Haghighi AB, Namazi MR. Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther. 2010;35:125–6.

    Article  PubMed  CAS  Google Scholar 

  88. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772–8.

    Article  PubMed  Google Scholar 

  89. Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium difficile-associated diarrhea. World J Gastroenterol. 2010;16:3573–7.

    Article  PubMed  CAS  Google Scholar 

  90. Namazi MR, Jowkar F. Can proton pump inhibitors accentuate skin aging? Arch Med Res. 2010;41:147–8.

    Article  PubMed  CAS  Google Scholar 

  91. Smith HS, Dhingra R, Ryckewaert L, Bonner D. Proton pump inhibitors and pain. Pain Phys. 2009;12:1013–23.

    Google Scholar 

  92. Rozgony NR, Fang C, Kuczmarski MF, Bob H. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder. 2010;29:87–99.

    Article  PubMed  Google Scholar 

  93. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(Suppl 2):5–9.

    Article  Google Scholar 

  94. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007;150:262–7.

    Article  PubMed  CAS  Google Scholar 

  95. Lucas LM, Gerrity MS, Anderson T. A practice-based approach for converting from proton pump inhibitors to less costly therapy. Eff Clin Pract. 2001;4:263–70.

    PubMed  CAS  Google Scholar 

  96. Pohland CJ, Scavnicky SA, Lasky SS, Good CB. Lansoprazole overutilization: methods for step-down therapy. Am J Manag Care. 2003;5:353–8.

    Google Scholar 

  97. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol. 2001;33:32–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Government Medical College, Thrissur, Kerala, 680596, India

    T. P. Rakesh

Authors
  1. T. P. Rakesh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. P. Rakesh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rakesh, T.P. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol 4, 53–59 (2011). https://doi.org/10.1007/s12328-011-0208-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-011-0208-y

Keywords

Search

Navigation